To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

Long Covid Clinical Trial

— BLOC  

Official title:

A Prospective, Double-blind, Randomized, Parallel Group, Placebo Controlled, Multicentre, Phase II Study to Investigate the Efficacy, GPCR Autoantibody Neutralizing Effect, Safety, and Tolerability of BC 007 in Participants With Long COVID

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05911009
• Other study ID #: SBC007C401
• Secondary ID: 2022-003452-14
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 16, 2023
• Est. completion date: May 31, 2025

Study information

• Verified date: April 2024
• Source: Berlin Cures GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an interventional, randomized, multinational, multicenter, double-blind, phase 2 study with a follow-up period of circa 12 months.

The intension of this clinical trial is to investigate the long-term sequelae (named Long COVID syndrome; post COVID or PASC) of an infection with Corona Virus Type 2 that has resulted in a condition known as Severe Acute Respiratory Syndrome Corona Virus Type 2 (SARS-CoV-2).

The purpose of this study is to evaluate the efficacy and safety of BC 007 as a treatment for long-lasting COVID-symptoms in patients who were neither intubated nor supported with extracorporeal blood oxygenation (ECMO) during their acute COVID-19 infection.

The study drug acts by neutralizing functional autoantibodies directed against G-protein coupled receptors (GPCRs).

Neutralization of the autoantibodies is expected to induce a beneficial effect on symptoms typically seen in patients with long COVID syndrome.

Functional autoantibodies are proteins belonging to the class of G-type immunoglobulins that can be synthesized by activation of the immune system and can induce various pathogenic activities by binding to one of the extracellular loops of G-proteins (GPCR-AAB).

The study consists of a screening phase of up to 35 days, treatment (two administrations by intravenous infusion at two-week intervals either with the study drug (BC 007) or with placebo (NaCl 0.9%), with an initial follow-up period of 15 days after each administration and an extended follow-up period of 330 days.

Patients are required to visit the study center for follow-up visits at specified intervals.

For the entire study duration of 395 days from screening to the end of the study, 11 site visits are planned.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 114
• Est. completion date: May 31, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participant is eligible to be included in the study only if all the following criteria apply:

1. The participant provides written informed consent prior to any clinical study-specific procedures.

2. The participant is a male or female, =18 years of age, at the time of signing the informed consent form.

3. All male and female participants of childbearing potential must be willing to use effective methods of contraception during the intervention period, and at least 6 months from the time of receiving the last dose of the study intervention. Male participants must refrain from donating sperm during this period.

4. Acute phase of COVID-19 ended at least 3 months prior to dosing.

5. The participant has a confirmed negative SARS-CoV-2 test result (polymerase chain reaction [PCR] test) at screening.

6. The participant provides a documented positive SARS-CoV-2 test result (reverse transcriptase [RT]-PCR or rapid antigen test) at Screening. For participants with long COVID symptoms who cannot provide certified evidence, a positive antibody test for nucleocapsid protein IgG must demonstrate a history of SARS CoV 2 infection; this test can be performed as part of the Screening procedure. The participant reports persistence or new onset of symptoms after a SARS-CoV-2 infection, with these symptoms lasting for at least 2 consecutive months (being persistent, recurrent, or of varying severity within that period) with no other explanation, as defined by WHO, and not being present prior to COVID-19 infection.

7. Participant is screened positive for GPCR-AAB activity by Berlin Cures laboratory.

8. Participant has not been intubated or received ECMO support during their acute COVID-19 infection.

9. Participant screens positive for fatigue (FACIT-FS score <35) and presents with at least one additional symptom from the symptom score sheet (COA) which has persisted for more than 12 weeks.

10. Participant is not on any permanent medication(s) to treat chronic diseases that existed prior to COVID 19 infection. Exceptions are clinically stable conditions, which do not affect the study assessments and may be allowed as judged by the Investigator after discussion with the medical monitor. Clinically unstable is defined as a diagnosis or condition requiring changes in disease management within 2 months prior to start of Screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition.

11. Participant reports that his/her activity level was not impaired prior to acute COVID 19 infection.

Exclusion Criteria:

Participant is excluded from the study if any of the following criteria apply:

1. Postural Orthostatic Tachycardia Syndrome existing prior to the initial SARS CoV 2 infection leading to long COVID, as per medical history. History or evidence of any clinically significant cardiovascular disease.

2. Any history or presence of gastrointestinal, endocrinologic (Type 1 diabetes,), haematologic, hepatic, immunologic, metabolic (specifically gout), urologic, pulmonary (asthma), neurologic, dermatologic, renal and/or other major disease or malignancy, as judged by the Investigator before SARS-CoV-2 infection.Other clinically stable conditions, which do not affect the study assessments may be allowed as judged by the Investigator after discussion with the medical monitor.

Possible allowed diseases are (if stable and well-controlled) include but are not limited to:

• Respiratory disorders (e.g., asthma-like) that first appear with long COVID.

• Mild hypertension (<160 mmHg systolic, <100 mmHg diastolic) without known organ or vessel damage.

• Non-insulin-dependent diabetes mellitus without known organ or vessel damage.

• Glaucoma.

• Hypercholesterolemia/hypertriglyceridemia.

• Hypothyreosis

3. Participants with history of major active or chronic unstable psychiatric illness (e.g., but not limited to, depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year.

4. Any history of any other chronic neurological, or psychological disease such as, but not limited to, chronic fatigue syndrome, fibromyalgia, lupus, Sjogren's syndrome.

Any history or presence of relevant allergic reactions (e.g., requiring hospital stay, intravenous [i.v.] treatment or treatment with systemic steroids). A participant will not be included if it is likely that seasonal allergic symptoms will require any kind of systemic treatment until Day 30 of the study.

5. Participant has a history of hypersensitivity to the study intervention or any of the excipients or to medicinal products with similar chemical structures.

6. Participant has any other condition, which in the opinion of the Investigator precludes the participant's participation in the clinical study.

7. Participant shows clinically significant abnormalities in clinical chemistry or haematology at screening, as judged by the Investigator.

8. Female participant is pregnant and/or breast feeding.

9. Participant participated in a previous clinical study (within 30 days or 5 half-lives of the investigational drug, or whichever is longer prior to start of Screening) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s).

10. Participant is an employee of the Sponsor, or contract research organization (CRO) conducting the study.

11. Participant has a close affiliation with the investigational site, e.g., a close relative of the Investigator, dependent person (e.g., employee or student of the investigational site).

12. Participant with an estimated glomerular filtration rate <60 mL/min/1,73 m².

13. Participant has alcohol addiction or history of alcohol addiction.

14. Participant has drug addiction or history of drug addiction.

15. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent or limit the ability of the participant to comply with the protocol requirements.

16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the last 5 years.

17. Participant has had comparable and prolonged symptoms after other viral infections (e.g., after Epstein-Barr virus infection, influenza, infectious mononucleosis).

18. Previous diagnosis of sleep apnoea.

19. Current use of medications with psychoactive properties that have a deleterious effect on cognition.

Related Conditions & MeSH terms

• Long Covid

Intervention

Drug:
• BC 007 or matching placebo
Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design

Locations

Country	Name	City	State
Austria	Klinik Favoriten - Wiener Gesundheitsverbund	Vienna
Austria	Klinik Floridsdorf - Wiener Gesundheitsverbund	Vienna
Finland	Terveystalo Helsinki Sleep Clinic	Helsinki	Nyland And Tavastehus County
Germany	Charité - Universitätsmedizin Berlin	Berlin
Germany	Krankenhaus Havelhöhe	Berlin
Germany	Universitätsklinikum Köln	Cologne	Nordrhein-Westfalen
Germany	Universitätsklinikum Erlangen	Erlangen	Bayern
Germany	Universitätsklinikum Freiburg	Freiburg	Baden-Württemberg
Germany	Universitätsklinikum Heidelberg	Heidelberg	Baden-Württemberg
Germany	Universitätsklinikum Jena	Jena	Thüringen
Germany	Universitätsklinikum Münster	Münster	Nordrhein-Westfalen
Spain	Hospital General Universitario de Alicante	Alicante	Valencia
Spain	Hospitalario Universitario Quironsalud Madrid	Madrid
Spain	Hospital General de Málaga	Málaga
Spain	University Hospital Virgen Del Rocio S.L.	Sevilla
Switzerland	Stadtspital Zurich Waid	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Berlin Cures GmbH

Countries where clinical trial is conducted

Austria,  Finland,  Germany,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline in score on FACIT-FS scale at Day 30.	To compare efficacy of BC 007 (double dose 1350 mg and double dose 1900 mg) with placebo based on Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale in long COVID participants.; FACIT-F is a five-point scale from 0 (not at all) to 4 (very much). The maximum composite scale is 52 (range 0 to 52). Higher scores mean a better outcome.	Day 30
Secondary	To compare GPCR AAB neutralizing effect of BC 007 1350 mg with that of placebo.	Proportion of participants sero-converting to negative for GPCR-AAB	at Days 3, 15, 17, 30, 90, 180 and Day 360 post first infusion of study intervention.
Secondary	To compare GPCR AAB neutralizing effect of BC 007 1900 mg with that of placebo.	Proportion of participants sero-converting to negative for GPCR-AAB	at Days 3, 15, 17, 30, 90, 180 and Day 360 post first infusion of study intervention.
Secondary	To compare GPCR-AAB neutralizing effect of BC 007 1350 mg with that of BC 007 1900 mg	Proportion of participants sero-converting to negative for GPCR-AAB	at Days 3, 15, 17, 30, 90, 180 and Day 360 post first infusion of study intervention.